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A s the Democratic Republic of Congo’s (DRC’s) 10th outbreak of Ebola virus disease (EVD) rages in this resource-limited, war-
torn region, advances in the delivery of supportive 
care and the introduction of in-
vestigational therapies provide a 
glimmer of hope amid the mount-
ing infections. In the absence of 
effective therapies or vaccines, 
EVD outbreak response has cen-
tered around the most basic of 
public health principles — iden-
tification and isolation of patients 
with suspected and confirmed 
EVD and tracking of all the con-
tacts of the confirmed patients, 
who are then rapidly isolated if 
they show signs of disease. This 
strategy of “identify, isolate, and 
track” allows public health re-
sponders to curtail and eventu-
ally eliminate virus transmission 
in the community and has been 
the foundation of EVD outbreak-
control efforts since the disease 
was first described in 1976.
Strategies for protecting sus-
ceptible communities have not al-
ways benefited patients, however. 
Within what were once routinely 
called EVD isolation units — now 
known as Ebola treatment units 
— supportive care was typically 
limited to the most basic mea-
sures, such as providing oral rehy-
dration salts and acetaminophen. 
Unsurprisingly, case fatality ratios 
were high, which fueled commu-
nity mistrust and resistance to 
broader outbreak-control efforts. 
The prolonged 2013–2016 EVD 
outbreak in West Africa allowed 
for an evolution of care that, by 
the time the outbreak was declared 
over, saw many patients receiving 
intravenous volume repletion, anti-
biotics, and antimalarials, poten-
tially contributing to the down-
ward trend in case fatality ratios.1,2 
In effect, as the epidemic waned, 
a new standard of care emerged, 
along with the important and en-
during lesson that substantial 
progress in the clinical care of pa-
tients with EVD was not only pos-
sible but most likely essential to 
improving patient outcomes.
The fact that basic supportive 
care for patients with EVD could 
be debated seems incongruous 
with the fundamental principles 
of clinical care. The management 
of other life-threatening infections 
— even those for which specific 
treatments exist, such as influenza 
and bacterial sepsis — often in-
volves a bundled approach to care 
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that comprises, at a minimum, 
adequate volume resuscitation, 
electrolyte monitoring and replace-
ment, and administration of sup-
plemental oxygen to stabilize and 
support essential organ functions, 
prevent further organ failure, and 
buy time while an antiinfective 
agent or the body’s own immune 
system fights the pathogen. The 
treatment of a patient with sepsis 
using antibiotics alone, without 
consideration of other aspects of 
recommended care, would be 
considered malpractice in most 
settings.
At the beginning of the West 
African EVD epidemic, a World 
Health Organization (WHO) clin-
ical expert team, together with 
Médecins sans Frontières (MSF) 
and health care providers from 
Guinea, achieved improved out-
comes by focusing on aggressive 
supportive care in line with this 
approach, including intravenous 
fluid resuscitation and, when op-
erational, electrolyte repletion di-
rected by point-of-care laboratory 
testing.1 As pragmatic as the pro-
vision of such supportive care may 
seem, however, it was not without 
challenges. As the epidemic pro-
gressed, several factors, including 
increasing ratios of patients to 
health workers, made it difficult 
to consistently provide this level 
of care. Furthermore, the limited 
numbers of experienced health 
workers and a hesitancy to per-
form procedures that could place 
workers at risk, such as insertion 
of intravenous catheters, also con-
strained universal uptake of ag-
gressive clinical management.
In contrast, the care of patients 
with EVD in countries where 
health resources were readily avail-
able looked very different. Such 
patients were treated by teams of 
health care professionals who ad-
ministered the highest levels of 
supportive critical care and were 
able to perform procedures that 
carried risks far greater than those 
associated with placing an intra-
venous line. Of the 27 patients 
with EVD who received treatment 
in the United States or Europe, 
only 5 died, corresponding to a 
case fatality ratio, expressed as a 
percentage, of 18.5% — substan-
tially lower than the case fatality 
ratio of 40 to 70% reported in 
West Africa.3,4 Eighty-five percent 
of patients in the United States 
and Europe also received one or 
more experimental therapies un-
der expanded-access protocols; 
such therapies were generally un-
available to patients in West Africa. 
Although conclusions about the ef-
ficacy and safety of both the inves-
tigational therapies and the sup-
portive care provided to certain 
patients cannot be reached outside 
a controlled research setting, it 
seems unlikely that investigational 
therapies alone were responsible 
for the difference in outcomes be-
tween patients in these settings. 
Rather, the provision of optimized 
supportive care, including ade-
quate volume repletion, active 
monitoring and management of 
laboratory abnormalities, and me-
chanical organ system support, 
most likely had an important ef-
fect on case fatality ratios.
There are clear logistic chal-
lenges associated with bringing 
this level of enhanced care to plac-
es where EVD outbreaks originate, 
but recent innovations in treat-
ment centers are enabling prog-
ress. In the DRC, the nongov-
ernmental organization Alliance 
for International Medical Action 
(ALIMA) introduced to the field 
the CUBE system — a portable, 
biosecure room with transparent 
walls that permits continuous ob-
servation, improved accessibility, 
and provision of basic clinical care 
from the low-risk zone of the 
Ebola treatment unit (see photo). 
Similarly, MSF’s laboratory tent 
straddles the treatment unit’s low- 
and high-risk zones, thereby al-
lowing staff to perform on-site 
laboratory testing, the results of 
which are critical to providing 
data-driven care. These innova-
tions increase health workers’ ca-
pacity to deliver supportive critical 
care and reflect the continued 
evolution toward patient-centered 
approaches that involve both iso-
lation and treatment.
A natural next step in the care 
of patients with EVD is treatment 
directed against the virus itself. 
Whereas a minority of West Afri-
can patients during the 2013–2016 
epidemic received either an inves-
tigational therapy or the type of 
supportive care that was available 
to virtually every patient treated 
outside Africa, almost all patients 
in the current DRC outbreak have 
had improved access to both forms 
of treatment because of implemen-
tation of the Monitored Emergency 
Use of Unregistered and Investi-
gational Interventions (MEURI) 
protocol.5 Under the MEURI um-
brella, the WHO clinical expert 
team and the Institut National 
de Recherche Biomédicale have 
partnered with ALIMA, MSF, and 
other groups to support the rapid 
scale-up of access to and safe de-
livery of investigational therapies, 
closely coupled with optimized 
supportive care. This experience 
demonstrating proof of capacity 
will ultimately provide an impor-
tant bridge to clinical research that 
will enable evaluation of therapeu-
tic efficacy and safety.
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The 2013–2016 West African 
EVD epidemic was declared a 
global public health emergency 
and led to global recognition that 
emerging infectious diseases once 
considered “tropical” in nature 
must now be considered global 
threats that can emerge in a re-
mote location one week and ap-
pear as new clusters of infections 
in even the most distant settings 
the next. Distance is no longer a 
reliable barrier to the spread of 
such diseases, but it has contin-
ued to determine the level of care 
a patient is able to receive. Within 
the broader context of the WHO’s 
universal health coverage and Sus-
tainable Development Goal initia-
tives, and as the treatment para-
digm for patients with EVD shifts 
from isolation to aggressive sup-
portive care and antiviral therapy, 
the global health community can 
build on existing momentum and 
work toward establishing univer-
sal standards of care in EVD 
management with a goal of elim-
inating the disparities that often 
dictate health care inequality.
It should no longer be accept-
able to have two standards of care 
— one for patients in resource-
constrained settings and another 
for those in countries where re-
sources are more readily available. 
The ongoing response to EVD is 
teaching us that higher standards 
are no longer aspirational but are 
possible, and that during inevi-
table future outbreaks of EVD, no 
matter how remote the setting, 
we can provide people who are 
sick and suffering with the type 
of care that we would want to re-
ceive.
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Health Workers in Beni, Democratic Republic of Congo, using the CUBE System to 
Monitor and Treat a Patient with EVD.
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